Kineta Appoints Internationally-Renowned Clinical Immuno-oncology Experts to its Scientific Advisory Board
SEATTLE, March 01, 2023 -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announce ...